About Bioline  All Journals  Testimonials  Membership  News  Donations

Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
ISSN: 1596-5996
EISSN: 1596-9827
Vol. 15, No. 1, 2016, pp. 201-211
Bioline Code: pr16028
Full paper language: English
Document type: Review Article
Document available free of charge

Tropical Journal of Pharmaceutical Research, Vol. 15, No. 1, 2016, pp. 201-211

 en Nanoformulations and Clinical Trial Candidates as Probably Effective and Safe Therapy for Tuberculosis
Laghari, Madeeha; Darwis, Yusrida; Memon, Abdul Hakeem; Khan, Arshad Ali; Abdulbaqi, Ibrahim Mohammed Tayeb & Assi, Reem Abou


Tuberculosis (TB) is the main infectious disease causing 1.8 million deaths worldwide every year and represents a principal cause of mortality resulting from a bacterial infection. The emergence of multidrug-resistant strains and lack of effective anti-TB drugs are threatening the future control of TB. The present multidrug regimen against TB needs daily administration for at least 6 months, and patients often fail to follow this complex regimen for such a long interval, thus leading to patient non-compliance and treatment related side effects. To avoid daily dosing, application of nanotechnology is a promising solution by virtue of sustained drug release. Nanotechnology-based rational targeting may improve therapeutic success by limiting adverse drug effects and requiring less frequent administration regimens, ultimately resulting in higher patient compliance, and thus attain higher adherence levels. Today, the pipeline of potential new treatments consists of several compounds in clinical trials or preclinical development with promising activities against sensitive and resistant Mycobacterium tuberculosis strains. Encapsulation of existing anti-TB drugs into nano-delivery systems and introduction of new drugs in combination treatment for all forms of tuberculosis have resulted in novel treatments with more effectiveness and reduced side effects.

Tuberculosis; Nanotechnology; Anti-tuberculosis drugs; Nano carriers; Rifampicin

© Copyright 2016 - Tropical Journal of Pharmaceutical Research
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2022, Site last up-dated on 19-Jan-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil